Delcath Systems (NASDAQ:DCTH) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a sell rating in a research note published on Thursday morning.

A number of other equities analysts have also commented on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Delcath Systems in a research report on Tuesday, August 6th. Stephens reissued an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a research report on Tuesday, August 6th. Finally, Craig Hallum started coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a “buy” rating and a $18.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Stock Performance

Shares of DCTH opened at $11.28 on Thursday. The firm has a market cap of $313.43 million, a PE ratio of -4.26 and a beta of 0.78. The firm’s 50 day moving average price is $9.12 and its 200 day moving average price is $7.75. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $11.74.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The business had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same period in the previous year, the business posted ($0.58) EPS. On average, sell-side analysts anticipate that Delcath Systems will post -1.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Delcath Systems

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new position in Delcath Systems during the second quarter worth $370,000. Levin Capital Strategies L.P. increased its position in Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after acquiring an additional 5,969 shares during the period. Renaissance Technologies LLC bought a new position in Delcath Systems during the second quarter worth $694,000. Marshall Wace LLP increased its position in Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after acquiring an additional 6,066 shares during the period. Finally, Legato Capital Management LLC bought a new position in Delcath Systems during the second quarter worth $966,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.